| ID | 117032 |
| 著者 | |
| キーワード | Glucagon-like peptide 1 receptor agonists (GLP-1 RAs)
Oral semaglutide (Rybelsus)
Sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC)
Peptide Innovation for early diabetes treatment (PIONEER)
Adverse effects (AEs)
|
| 資料タイプ |
学術雑誌論文
|
| 抄録 | As one of the Glucagon-like peptide 1 receptor agonists (GLP-1 RAs), oral semaglutide (Rybelsus) become first ingestible agent by absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC). It was clinically investigated by Peptide InnOvatioN for Early diabEtes tReatment (PIONEER) trials. Pharmacologically, blood concentration of semaglutide is kept higher when fasting time period after intake becomes longer. It is provided for increasing doses of 3 mg, 7 mg, 14 mg in every month. Rybelsus showed higher ratio of adverse effects (AEs), which include gastrointestinal dysfunction and headache. This agent is a novel delivery of therapeutic peptide and become life-changing beneficial agents for diabetic patients.
|
| 掲載誌名 |
Journal of Diabetes, Obesity & Metabolism
|
| 出版者 | Yumed Text
|
| 巻 | 5
|
| 号 | 1
|
| 開始ページ | e108
|
| 発行日 | 2022-04-24
|
| 権利情報 | Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/).
|
| 出版社版URL | |
| フルテキストファイル | |
| 言語 |
eng
|
| 著者版フラグ |
出版社版
|
| 部局 |
医学系
|
